Harel Insurance Investments & Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-933
Closed -$390K 733
2020
Q4
$390K Hold
933
0.01% 397
2020
Q3
$136K Buy
+933
New +$133K ﹤0.01% 358
2020
Q1
Sell
-572
Closed -$66K 434
2019
Q4
$66K Buy
572
+440
+333% +$43.9K ﹤0.01% 338
2019
Q3
$11K Hold
132
﹤0.01% 434
2019
Q2
$10K Sell
132
-2,000
-94% -$153K ﹤0.01% 422
2019
Q1
$210K Sell
2,132
-185
-8% -$15.5K 0.01% 121
2018
Q4
$169K Buy
2,317
+39
+2% +$3K 0.01% 187
2018
Q3
$200K Buy
2,278
+1,953
+601% +$196K 0.01% 201
2018
Q2
$32K Hold
325
﹤0.01% 348
2018
Q1
$39K Sell
325
-95
-23% -$12.2K ﹤0.01% 327
2017
Q4
$53K Buy
420
+230
+121% +$28.9K ﹤0.01% 317
2017
Q3
$22K Buy
+190
New +$16.2K ﹤0.01% 334
2016
Q4
Sell
-210
Closed -$14K 370
2016
Q3
$14K Sell
210
-20
-9% -$1.41K ﹤0.01% 351
2016
Q2
$13K Buy
230
+80
+53% +$5.04K ﹤0.01% 525
2016
Q1
$9K Hold
150
﹤0.01% 363
2015
Q4
$14K Buy
+150
New +$13.9K ﹤0.01% 278

Other funds holding ALNY

Harel Insurance Investments & Financial Services's ALNY Position: Q1 2021 in Review

Harel Insurance Investments & Financial Services sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2021, closing a stake of 933 shares — an estimated $390K sold.

Harel Insurance Investments & Financial Services first reported a position in ALNY in Q4 2015 and held it in 16 quarters. The position peaked at $390K in Q4 2020. 391 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

  • Harel Insurance Investments & Financial Services reported no remaining Alnylam Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 933 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $390K.
  • Harel Insurance Investments & Financial Services first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 16 quarters.
  • Harel Insurance Investments & Financial Services's Alnylam Pharmaceuticals position peaked at $390K in Q4 2020.
  • 391 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q1 2021, filed 27 Apr 2021.